<SEC-DOCUMENT>0001062822-24-000051.txt : 20240916
<SEC-HEADER>0001062822-24-000051.hdr.sgml : 20240916
<ACCEPTANCE-DATETIME>20240916065146
ACCESSION NUMBER:		0001062822-24-000051
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240913
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240916
DATE AS OF CHANGE:		20240916

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXICON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001062822
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				760474169
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30111
		FILM NUMBER:		241299292

	BUSINESS ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381
		BUSINESS PHONE:		2818633000

	MAIL ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON PHARMACEUTICALS, INC./DE
		DATE OF NAME CHANGE:	20070426

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON GENETICS INC/TX
		DATE OF NAME CHANGE:	20000126
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lxrx-20240913.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:e64217b6-d9eb-4b22-86cf-3a4eeef618ad,g:6b131c0f-8667-4c83-92c7-745bae030325,d:1f3d2a80dab44a59bbe74bd94d703465-->
<html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lxrx-20240913</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001062822</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lxrx-20240913.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-03</xbrli:startDate><xbrli:endDate>2024-07-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1f3d2a80dab44a59bbe74bd94d703465_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">September 13, 2024</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Lexicon Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.274%"><tr><td style="width:1.0%"/><td style="width:32.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.091%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.854%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">000-30111</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">76-0474169</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">2445 Technology Forest Blvd., 11th Floor</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">The Woodlands</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Texas</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">77381</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices and Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">281</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">863-3000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"/><td style="width:34.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.904%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.372%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-13">Common Stock, par value $0.001</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-14">LXRX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-15">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17&#160;CFR&#160;230.425)</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17&#160;CFR 240.14a-12)</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-18">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17&#160;CFR 240.14d-2(b))</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-19">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17&#160;CFR&#160;240.13e-4(c))</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></div><div style="margin-bottom:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1f3d2a80dab44a59bbe74bd94d703465_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 5.02 &#160;&#160;&#160;&#160;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)         On September 13, 2024, we and Jeffrey L. Wade determined that his employment as our president and chief operating officer (in which capacity, Mr. Wade has functioned as our principal financial officer) would terminate as of September 30, 2024.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In connection with the termination of his employment, we entered into a separation agreement with Mr. Wade providing that we will pay Mr. Wade salary continuation payments in an amount equal to his current base annual salary of $585,000 for a period of twelve months following the date of his termination of employment (the &#8220;Separation Date&#8221;).  We will also pay Mr. Wade an additional, lump sum payment of $175,500, or 50% of his current target cash bonus, payable within 30 days of the Separation Date.  In addition, we will make monthly payments of $3,700 for a period of 12 months to provide for his cost of continued benefit coverage under COBRA during such period and provide certain executive outplacement services.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Also in connection with the termination of his employment, we entered into a consulting agreement with Mr. Wade on September 13, 2024 pursuant to which he will provide his consulting and advisory services for a period of eight months following the date of his termination of employment and we will pay Mr. Wade fees of $3,000 per month.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Copies of the separation agreement and consulting agreement are attached to this current report on Form 8-K as Exhibit 10.1 and 10.2, respectively, and the above summaries are qualified in their entirety by reference to the full text of such agreements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)         Effective as of the date of termination of Mr. Wade&#8217;s employment, Kristen L. Alexander will assume the function of our principal financial officer.  Ms. Alexander, 56, has been our vice president, finance and accounting and principal accounting officer since September 2021 and previously served as controller since joining our company in 2017.  Ms. Alexander previously served as controller of Johnson Specialty Tools, LLC and in a variety of finance and accounting management positions for Trican Well Services, L.P., Nabors Industries Ltd. and Ernst &amp; Young, LLP.  Ms. Alexander is a certified public accountant and received her B.B.A. from the University of Oklahoma.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(e)         The information set forth in the second and third paragraphs of Item 5.02(b) is incorporated herein by reference.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i1f3d2a80dab44a59bbe74bd94d703465_10"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 9.01 &#160;&#160;&#160;&#160;Financial Statements and Exhibits</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Exhibits </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"/><td style="width:13.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:76.061%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh101wadeseparationagreem.htm">Separation Agreement, dated September 13, 2024, with Jeffrey L. Wade</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh102wadeconsultingagreem.htm">Consulting Agreement, dated September 13, 2024, with Jeffrey L. Wade</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EX-104</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1f3d2a80dab44a59bbe74bd94d703465_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Signatures</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"/><td style="width:52.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.447%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.423%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lexicon Pharmaceuticals, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date:   September 16, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">/s/ Brian T. Crum</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Brian T. Crum</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Senior Vice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">President and General Counsel</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exh101wadeseparationagreem.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="iefd9bab6adb44d94ba8875a19adffc3f_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">September 13, 2024</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Jeffrey L. Wade</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Address&#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dear Jeff&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The purpose of this letter is to confirm our agreement concerning your resignation as President and Chief Operating Officer of Lexicon Pharmaceuticals, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of September 30, 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Separation Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), you hereby resign as President and Chief Operating Officer of the Company. In connection with such resignation, you also hereby resign from any positions you currently hold as an officer or member of the boards of directors of any affiliates of the Company. We agree that this letter constitutes, and is deemed to satisfy all obligations with respect to, notice of termination as set forth in Section 7 of the Employment Agreement between you and the Company, dated January 1, 1999, as subsequently amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Employment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and no additional notice of termination will be required under the Employment Agreement. Your resignation pursuant to this letter will be treated for all purposes as a voluntary termination of your employment by you and the parties agree that, in consideration for the Severance Benefits provided herein, no payments will be due pursuant to Section 6(b) of the Employment Agreement as a result of such resignation.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding the voluntary character of your separation, and subject to the requirements of the following paragraph, the Company hereby agrees to pay (so long as you satisfy the requirements set forth in the following paragraph) to you the following (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-20.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:16.55pt">Salary continuation payments (pursuant to the Company&#8217;s normal payroll procedures) in an amount equal to your current base annual salary of $585,000, less applicable tax withholding, for a period of twelve (12) months following the Separation Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Severance Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, (i) the first installment of the Severance Payment shall be paid on the Company&#8217;s first regular pay date for executive employees that comes after the Release (as defined below) has been timely signed and returned to the Company by you and any applicable revocation period set forth in the Release has expired without you having exercised your revocation right, and such installment payment shall include (without interest) the number of installment payments of the Severance Payment that you would have received had such installments been paid on the Company&#8217;s regular pay dates for executive employees between the Separation Date and the date of such first installment payment, and (ii) the remainder of the installments of the Severance Payment shall be paid on the Company&#8217;s regular pay dates for executive employees that come after such first installment pay date and that are attributable to the remainder of the pay periods during the twelve (12) months following the Separation Date&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-20.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:16.55pt">An additional lump sum payment equal to 50% of your current target cash bonus ($175,500), less applicable tax withholding, payable within 30 days following the Separation Date&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-20.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:16.55pt">Monthly payments equal to $3,700, less applicable taxes and other withholdings, on the regular monthly pay dates of the Company for executive employees for the twelve (12) months that follow the Separation Date, which payments shall be paid on the same installment schedule as set forth above for the Severance Payment, and which payments are intended to provide for the cost of continued benefit coverage under COBRA in accordance with your benefit coverage elections in effect immediately prior to the Separation Date (provided, however, you acknowledge and agree that it shall be your sole responsibility to elect COBRA coverage and pay the applicable COBRA premiums)&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-20.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:16.55pt">Certain executive outplacement services to be agreed by the parties and reasonably acceptable to you.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Your eligibility to receive the Severance Benefits (and any portion thereof) is subject to your&#58; (i) execution on or after the Separation Date (but before the Release Expiration Date), and return to the Company on or before the Release Expiration Date, of a release of all claims in a form acceptable to the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), which Release shall release the Company and each of its affiliates, and the foregoing entities&#8217; respective shareholders, members, partners, officers, managers, directors, predecessors, successors, fiduciaries, employees, representatives, agents and benefit plans (and fiduciaries of such plans) from any and all claims, including any and all causes of action arising out of your employment, engagement, or affiliation with the Company or any of its affiliates or the termination of such employment, engagement or affiliation, but excluding all claims to Severance Benefits as described herein&#59; (ii) non-revocation of the Release within any time set forth within the Release for you to do so&#59; and (iii) continued compliance with all post-employment obligations that you have to the Company or any of its affiliates, including as set forth in Section 10 and, as modified hereby, Section 13 of the Employment Agreement.  As used herein, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Release Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; is that date that is twenty-one (21) days following the date upon which the Company delivers the Release to you (which shall occur no later than three (3) days after the Separation Date).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This letter is intended to comply with Section 409A of the Internal Revenue Code of 1986, as amended (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), or to be excluded from Section 409A, as applicable, and shall be construed and administered in accordance with such intent. Notwithstanding any other provision of this letter, payments provided pursuant to this letter may only be made upon an event and in a manner that complies with Section 409A or an applicable exemption. Any payments provided for within this letter that may be excluded from Section 409A either as separation pay due to an involuntary separation from service or as a short-term deferral, shall be excluded from Section 409A to the maximum extent possible. Each installment payment payable pursuant to this agreement shall be treated as a separate payment for purposes of Section 409A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided pursuant to this letter comply with Section 409A and in no event shall the Company be liable for all or any portion of any taxes, penalties, interest, or other expenses that may be incurred by you on account of non-compliance with Section 409A.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The parties agree that, notwithstanding any provisions of Section 10(e) of the Employment Agreement to the contrary, you may retain any Confidential Information (as defined </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4858-1278-4353v.3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in the Employment Agreement) in your possession, custody or control to the extent and for long as such retention may be necessary or required for you to fulfill your obligations under the consulting agreement entered into between you and the Company dated September 13, 2024 (the &#8220;Consulting Agreement&#8221;).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The parties further agree that Section 11 of the Employment Agreement is hereby terminated and that Section 13 of the Employment Agreement is hereby amended to provide that Employee&#8217;s obligations under Section 13 shall terminate upon the expiration or earlier termination of the Consulting Agreement.  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">It is agreed that, except as expressly provided herein, this letter shall not affect the rights and obligations of the parties under the Employment Agreement (including, without limitation, Sections 6(a), 10, 12 and , as modified hereby, 13 thereof) or any other agreements between the parties.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Signature page follows.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#93;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4858-1278-4353v.3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the foregoing correctly sets forth our mutual understanding, please so indicate by signing this letter in the space provided below and return it to the Company at the below address, whereupon this letter agreement shall constitute a binding contract between you and the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accepted and agreed to on the date set forth below&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:219.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LEXICON PHARMACEUTICALS, INC.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:220.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58;  _________________________________</font></div><div style="text-align:justify;text-indent:243pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Michael S. Exton, Ph.D.</font></div><div style="text-align:justify;text-indent:243pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Chief Executive Officer</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accepted and agreed to on the date set forth below&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; _______________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Jeffrey L. Wade</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Date&#58;  September 13, 2024</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4858-1278-4353v.3</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exh102wadeconsultingagreem.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="if99b075234ad4f9f98b15cc77005412a_1"></div><div style="min-height:94.5pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.2</font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">September 13, 2024</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Jeffrey L. Wade</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Address&#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dear Jeff&#58;</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are pleased to invite you to become a consultant to Lexicon Pharmaceuticals, Inc. (which, together with its subsidiaries and affiliates, is referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Lexicon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  The purpose of this letter agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is to set forth our mutual understanding of the terms and conditions under which you will provide consulting services to the Company, as set forth below.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Consulting Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  You will provide consulting services as the Company&#8217;s Chief Executive Officer or his designee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Designated Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) may request from time to time, which shall include providing consultation and advice relating to the Company&#8217;s financial, commercial and business development activities (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  You will devote up to 6 days during the term of this Agreement to providing such Services to the Company under this Agreement, on a schedule and at times reasonably agreed upon by you and the Designated Representative.  It is the intent of the parties that you will &#8220;separate from service&#8221; with the Company and its applicable affiliates pursuant to the rules and regulations of Section 409A of the Internal Revenue Code of 1986, as amended (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) immediately prior to the start of your consulting Services, therefore, notwithstanding anything to the contrary within this Section 1, in no event shall you be requested to perform Services in excess of an amount that the Company deems necessary to maintain such a separation from service with the Company and its applicable affiliates.  </font></div><div style="text-align:justify;text-indent:54pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  As full consideration for your Services as a consultant to the Company hereunder, you will receive a consulting fee of $3,000 per month during the term of this Agreement, payable in monthly installments.  In addition, you will be reimbursed for your reasonable, ordinary and necessary out-of-pocket expenses for attendance at in-person meetings or otherwise incurred at the Company&#8217;s request in connection with your performance of the Services, in accordance with the Company&#8217;s policies and procedures for reimbursement payments.</font></div><div style="text-align:justify;text-indent:54pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Confidential Information</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any of Company&#8217;s proprietary or confidential information provided to you by the Company or received by you in the course of providing services to the Company, whether before or after the date of this Agreement, regardless of whether such information is provided to, or received by, you orally, visually, electronically or in writing. Confidential Information shall include inventions, discoveries, improvements, materials, data, technology, processes, formulas, know-how, trade secrets, ideas and all other information which&#58; (i) gives the Company a competitive advantage by virtue of it not being generally known to the public, or (ii) otherwise meets the definition of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4888-1393-8401v.3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:94.5pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Jeffrey L. Wade</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">September 13, 2024</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Page 2</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Confidential Information.&#8221; Confidential Information shall not include any information generally available to the public other than as a result of any breach by you of any obligation that you owed to the Company. You agree to hold all Confidential Information in strict confidence and to take all reasonable precautions to protect Confidential Information, not to disclose any such Confidential Information to any third party, and to use Confidential Information only in furtherance of your Services under this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that your nondisclosure obligation shall not apply to the extent such Confidential Information (i) is already in the public domain or hereafter enters the public domain other than through your acts or omissions in violation of this Agreement&#59; or (ii) is hereafter received by you without restriction as to confidentiality or use from a third party lawfully entitled so to disclose same in such manner.  Information shall not be deemed to be within the foregoing exceptions merely because such information is embraced by more general information in the public domain or in your possession.  All Confidential Information (and any copies and notes thereof) shall remain the sole property of the Company. </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">You agree not to disclose or otherwise make available to the Company any information that you possess under an obligation of confidentiality to a third party.  You may disclose to the Company any information made available generally to the scientific community at large through published reports or public presentations prior to disclosure to the Company.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">Notwithstanding the foregoing, nothing in this Agreement or in any other agreement between you and the Company shall prevent you from&#58; (i) initiating communications directly with, cooperating with, providing information to, causing information to be provided to, or otherwise assisting in an investigation by, any governmental agency (including, for the avoidance of doubt, the Securities and Exchange Commission, Department of Justice, Department of Labor, any Inspector General or any other governmental agency, commission, or regulatory authority) regarding a possible violation of any law&#59; (ii) responding to any inquiry or legal process directed to Employee from any governmental agency&#59; (iii) testifying, participating or otherwise assisting in any action or proceeding by any governmental agency relating to a possible violation of law&#59; or (iv) making any other disclosures that are protected under the whistleblower provisions of any applicable law.  Nothing in this Agreement or in any other agreement with the Company requires you to obtain prior authorization before engaging in any conduct described in the previous sentence, or to notify the Company that you have engaged in any such conduct.  Additionally, pursuant to the federal Defend Trade Secrets Act of 2016, an individual shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that&#58; (A) is made (1) in confidence to a federal, state or local government official, either directly or indirectly, or to an attorney and (2) solely for the purpose of reporting or investigating a suspected violation of law&#59; (B) is made to the individual&#8217;s attorney in relation to a lawsuit for retaliation against the individual for reporting a suspected violation of law&#59; or (C) is made in a complaint or other document filed in a lawsuit or proceeding, if such filing is made under seal.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4888-1393-8401v.3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:94.5pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Jeffrey L. Wade</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">September 13, 2024</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Page 3</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Inventions and Discoveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">You hereby assign and transfer to the Company all of your right, title and interest throughout the world in any inventions, discoveries, improvements, materials, data, works of authorship and other intellectual property, whether or not patentable or subject to copyright, which may be made, written or conceived by you in the course of your performance of the Services, in whole or in part and whether alone or in conjunction with others (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  All Intellectual Property shall be the sole property of the Company or its nominee.  </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">You shall promptly disclose any Intellectual Property in writing to the Company in order to permit the Company to claim rights to which it may be entitled under this Agreement.  The Company shall have full power and authority to file and prosecute patent applications and copyright registrations throughout the world with respect to all Intellectual Property, and to procure and maintain patents and copyrights with respect thereto. You agree, at the Company&#8217;s reasonable request and expense, to sign, execute and acknowledge, or cause to be signed, executed and acknowledged, any applications, assignments, instruments and other documents, and to perform such other acts, as the Company may deem necessary, useful or convenient to confirm and vest in the Company or its nominee all right, title and interest throughout the world in and to any Intellectual Property and all patent, copyright and other intellectual property rights and protections therein, and to assist the Company in procuring, maintaining, enforcing and defending such patent, copyright and other intellectual property rights and protections throughout the world, at Company&#8217;s cost. Any Confidential Information contained in such Intellectual Property shall be treated as Confidential Information under this Agreement.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Conflicting Engagements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  During your service as a consultant to the Company, you agree that you will not, without previously notifying the Company in writing, directly or indirectly, become associated with, render advisory, consulting or other services to, or become employed by any other person or entity engaging in the commercialization or clinical development of a drug (i) in direct conflict or competition with a drug being commercialized by the Company or a Phase 3 drug development program being conducted by the Company or (ii) which inhibits or otherwise modulates a drug target that, as of the date of this Agreement, is the subject of any drug development program which is being conducted by the Company or any drug discovery program to which the Company is devoting material resources (collectively referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Third Party Competitors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  You agree to disclose to the Company any proposed relationship with a Third Party Competitor (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Proposed Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) at least 30 days prior to the establishment of a confidential relationship between you and such Third Party Competitor.  Upon such disclosure, the Company may consent to the Proposed Relationship in writing, may proffer written consent subject to condition precedent regarding certain restrictions on the scope and&#47;or field of the Proposed Relationship, or may terminate this Agreement. </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Term and Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  You will render the Services to the Company for an initial period commencing on the date of the termination of your employment with the Company and terminating on May 31, 2025, at which time this Agreement will terminate unless renewed by mutual written consent.  Notwithstanding the foregoing, this Agreement may be terminated prior </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4888-1393-8401v.3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:94.5pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Jeffrey L. Wade</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">September 13, 2024</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Page 4</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to May 31, 2025&#58; (a) at any time by you, with or without cause, upon 30 days&#8217; advance written notice to the Company, (b) by the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as provided in Section 5, with or without cause, upon written notice to you, or (c) by either party for breach of this Agreement by the other party that, where curable, is not cured within 10 business days after written notice of such breach is delivered to the breaching party.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Independent Contractor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  For purposes of this Agreement, and in the course of performing all Services hereunder, you will be deemed an independent contractor and not an employee or agent of Lexicon. In this connection, you will not be eligible for, nor entitled to, any employee benefits that extend to our employees (other than any benefits to which you may be entitled by virtue of your prior employment with the Company before the term of your service hereunder began), and we will not withhold any taxes from the compensation paid to you hereunder, all of which shall be your responsibility. The manner in which you render the Services will be within your reasonable control and discretion.  You have no express or implied authority to incur any liability, or to make any decision or to create any binding obligation, on our behalf and, in performing the Services you shall not have any power to bind or commit the Company or otherwise act on the Company&#8217;s behalf.  You agree that you shall not at any time communicate or represent to any third party, or cause or knowingly permit any third party to assume, that in performing the Services hereunder, you are an employee, agent or other representative of the Company or have any authority to bind the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance with Laws and Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.   To the extent you provide any Services on our premises, you agree to observe our rules, policies and security procedures concerning conduct and the health, safety and protection of persons and property. You will comply with all applicable governmental laws, ordinances, rules and regulations applicable to the performance of the Services.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of Texas as they apply to contracts entered into and wholly to be performed in Texas.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  You agree that a breach of any of the restrictions set forth in the provisions of this Agreement may cause the Company irreparable injury and damage, and that, in the event of any breach or threatened breach, the Company, in addition to all other rights and remedies at law or in equity, shall have the right to seek to enforce the specific performance of such restrictions and to apply for injunctive relief against their violation.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Survival of Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The provisions of Sections 3, 4 and 9 through 18 hereof shall survive termination of this Agreement.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Agreement is personal to you, and you may not assign this Agreement without the written consent of the Company.  This Agreement shall be binding on your heirs, executors, administrators and legal representatives and the Company&#8217;s successors and assigns.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The invalidity or unenforceability of any provision of this Agreement (or portion thereof) shall not affect the validity or enforceability of any other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4888-1393-8401v.3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:94.5pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Jeffrey L. Wade</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">September 13, 2024</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Page 5</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">provision of this Agreement, and if such provision (or portion thereof) is so broad as to be unenforceable, it shall be interpreted to be only as broad as is enforceable.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Agreement constitutes the sole and complete agreement of the parties with respect to the matters included herein, and supersedes any previous oral or written agreement, if any, relating to the subject matters included herein&#59; provided, however, this Agreement complements and is in addition to, all other obligations that you have to the Company with respect to confidentiality, non-disclosure, return of property, and intellectual property assignment (regardless of whether such obligation arises by contract, statute, common law, or otherwise).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment and Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Agreement may not be amended or supplemented in any way, nor may the benefit of any provision hereof be waived, except by a written agreement duly executed by both you and the Company.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Agreement is intended to comply with Section 409A, or to be excluded from Section 409A, as applicable, and shall be construed and administered in accordance with such intent. Notwithstanding any other provision of this Agreement, payments provided pursuant to this Agreement may only be made upon an event and in a manner that complies with Section 409A or an applicable exemption. Each installment payment payable pursuant to this Agreement shall be treated as a separate payment for purposes of Section 409A. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided pursuant to this Agreement comply with Section 409A and in no event shall the Company be liable for all or any portion of any taxes, penalties, interest, or other expenses that may be incurred by you on account of non-compliance with Section 409A.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Conflict</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  You represent that the performance of your obligations and duties under this Agreement does not conflict with any obligations or duties, express or implied, that you may have to third parties.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Each party to this Agreement has had the opportunity to review this Agreement with legal counsel.  This Agreement shall not be construed or interpreted against any party on the basis that such party drafted or authored a particular provision, parts of or the entirety of this Agreement.</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4888-1393-8401v.3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:94.5pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Jeffrey L. Wade</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">September 13, 2024</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Page 6</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the foregoing correctly sets forth our mutual understanding, please so indicate by signing this letter in the space provided below and return it to the Company at the above address, whereupon this Agreement shall constitute a binding contract between you and the Company.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accepted and agreed to on the date set forth below&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:255.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LEXICON PHARMACEUTICALS, INC.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:220.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; ____________________________</font></div><div style="padding-left:36pt;text-align:justify;text-indent:243pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Michael S. Exton, Ph.D.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:243pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Chief Executive Officer</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accepted and agreed to on the date set forth below&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; _____________________________</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Jeffrey L. Wade</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Date&#58;  September 13, 2024</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4888-1393-8401v.3</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>lxrx-20240913.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:e64217b6-d9eb-4b22-86cf-3a4eeef618ad,g:6b131c0f-8667-4c83-92c7-745bae030325-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lxrx="http://lexpharma.com/20240913" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://lexpharma.com/20240913">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20240913_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20240913_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://lexpharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>lxrx-20240913_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:e64217b6-d9eb-4b22-86cf-3a4eeef618ad,g:6b131c0f-8667-4c83-92c7-745bae030325-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_7a8d0f03-8869-4ba1-b857-0081cb2071e8_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_a2bf2951-d413-4746-9aff-2cda50eabe33_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3bc3147a-3bc3-4fb5-82f1-96be9277cebb_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_79adef0f-6847-456f-94c6-33ad4d33eca0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_81a8ebc2-ff58-494e-8276-5042921861f3_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_fee294d0-2775-402e-83ff-f87500d2fd69_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_25a46974-6332-4589-96c6-a95fe7935ee9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_dbda85b0-68ae-4a76-bc57-b45b78c4b1c9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_322c485c-ecdb-4206-91ce-a7e18fb28444_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_402eaf3a-8eea-4dd9-9c47-2f65e43dc4a3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_e2fe699c-728c-428d-8d75-6102cb5cf942_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e2f6fe6b-1f96-4fc7-8715-a2174f6f23d8_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_eac722c6-fbae-48bc-be8c-5898b99dd1be_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d84adc59-bc5e-4930-83e7-16235b2f458c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a32a24ec-11c1-45aa-adc8-0c053bcb2615_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b4b00b16-56af-44cf-a46c-d1b1b0e7c889_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d7f5e40b-8000-4aa2-aa06-ab1318a752f3_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_db4178ff-7102-4729-802e-3b7490d51c9e_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_51293875-a39f-41be-bca1-486ee963f299_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_de87545d-f7a8-43ca-9af7-f2d84392d9e0_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ea0b32a8-5259-4feb-8cf9-42d87b5ddb23_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_d5c90a4b-9317-45ac-9143-35b806d661b6_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>lxrx-20240913_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:e64217b6-d9eb-4b22-86cf-3a4eeef618ad,g:6b131c0f-8667-4c83-92c7-745bae030325-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://lexpharma.com/role/Cover" xlink:type="simple" xlink:href="lxrx-20240913.xsd#Cover"/>
  <link:presentationLink xlink:role="http://lexpharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_f1d3e92a-d18a-4c62-8236-9504c4ac1d8e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_382acc44-2c8d-4a3f-8c7d-0deba9ecb4f3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1d3e92a-d18a-4c62-8236-9504c4ac1d8e" xlink:to="loc_dei_DocumentType_382acc44-2c8d-4a3f-8c7d-0deba9ecb4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_9f52d6d2-e197-42c7-9539-858281d03816" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1d3e92a-d18a-4c62-8236-9504c4ac1d8e" xlink:to="loc_dei_EntityTaxIdentificationNumber_9f52d6d2-e197-42c7-9539-858281d03816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_604838b4-60f5-47ba-89b1-d36d4a3b30a3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1d3e92a-d18a-4c62-8236-9504c4ac1d8e" xlink:to="loc_dei_EntityRegistrantName_604838b4-60f5-47ba-89b1-d36d4a3b30a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a4c0cae7-dc35-4a57-a1e2-112aff7d89c8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1d3e92a-d18a-4c62-8236-9504c4ac1d8e" xlink:to="loc_dei_EntityFileNumber_a4c0cae7-dc35-4a57-a1e2-112aff7d89c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_57b27844-1fd9-4db9-914c-413fe887d3ac" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1d3e92a-d18a-4c62-8236-9504c4ac1d8e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_57b27844-1fd9-4db9-914c-413fe887d3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c83973e3-daf4-4e8d-b454-5443c73b0573" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1d3e92a-d18a-4c62-8236-9504c4ac1d8e" xlink:to="loc_dei_EntityAddressAddressLine1_c83973e3-daf4-4e8d-b454-5443c73b0573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_754fde32-d8ae-4975-98ab-ba29733cc0f6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1d3e92a-d18a-4c62-8236-9504c4ac1d8e" xlink:to="loc_dei_EntityAddressCityOrTown_754fde32-d8ae-4975-98ab-ba29733cc0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c53208e8-06f8-4709-894c-015c8da219f1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1d3e92a-d18a-4c62-8236-9504c4ac1d8e" xlink:to="loc_dei_EntityAddressStateOrProvince_c53208e8-06f8-4709-894c-015c8da219f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_38459432-592f-4a5a-9d15-f37b0c89fc55" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1d3e92a-d18a-4c62-8236-9504c4ac1d8e" xlink:to="loc_dei_EntityAddressPostalZipCode_38459432-592f-4a5a-9d15-f37b0c89fc55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ee03d4d2-b3b1-4348-bdc3-ef104c69bc0d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1d3e92a-d18a-4c62-8236-9504c4ac1d8e" xlink:to="loc_dei_CityAreaCode_ee03d4d2-b3b1-4348-bdc3-ef104c69bc0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c58fb05a-557e-4564-a410-05c3c303da31" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1d3e92a-d18a-4c62-8236-9504c4ac1d8e" xlink:to="loc_dei_LocalPhoneNumber_c58fb05a-557e-4564-a410-05c3c303da31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_9fb721c5-47de-4b4b-8397-37e48750768b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1d3e92a-d18a-4c62-8236-9504c4ac1d8e" xlink:to="loc_dei_Security12bTitle_9fb721c5-47de-4b4b-8397-37e48750768b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d978f866-7d48-4c55-9267-86f7e3384f1e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1d3e92a-d18a-4c62-8236-9504c4ac1d8e" xlink:to="loc_dei_TradingSymbol_d978f866-7d48-4c55-9267-86f7e3384f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6c7b6a5e-f825-422f-aa70-ba1b299cc7e9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1d3e92a-d18a-4c62-8236-9504c4ac1d8e" xlink:to="loc_dei_SecurityExchangeName_6c7b6a5e-f825-422f-aa70-ba1b299cc7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_d3a8305d-eb1f-4127-8beb-756e36c5cf8b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1d3e92a-d18a-4c62-8236-9504c4ac1d8e" xlink:to="loc_dei_WrittenCommunications_d3a8305d-eb1f-4127-8beb-756e36c5cf8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_33ed0dc6-c48d-4fa0-bf7b-6a8cfd84b469" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1d3e92a-d18a-4c62-8236-9504c4ac1d8e" xlink:to="loc_dei_SolicitingMaterial_33ed0dc6-c48d-4fa0-bf7b-6a8cfd84b469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_28d7450d-7eb5-4dc1-9e86-74a438289b60" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1d3e92a-d18a-4c62-8236-9504c4ac1d8e" xlink:to="loc_dei_DocumentPeriodEndDate_28d7450d-7eb5-4dc1-9e86-74a438289b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_61934aec-3955-482e-bfbd-86eb6d741ace" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1d3e92a-d18a-4c62-8236-9504c4ac1d8e" xlink:to="loc_dei_AmendmentFlag_61934aec-3955-482e-bfbd-86eb6d741ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a85b7d55-eeca-4f50-a5c1-940d3527f6ab" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1d3e92a-d18a-4c62-8236-9504c4ac1d8e" xlink:to="loc_dei_EntityCentralIndexKey_a85b7d55-eeca-4f50-a5c1-940d3527f6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_89ba076c-5aea-4302-951d-732b1a804a2e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1d3e92a-d18a-4c62-8236-9504c4ac1d8e" xlink:to="loc_dei_PreCommencementTenderOffer_89ba076c-5aea-4302-951d-732b1a804a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_fb55c9f2-c17f-4aa0-bf1f-54c099792b02" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1d3e92a-d18a-4c62-8236-9504c4ac1d8e" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_fb55c9f2-c17f-4aa0-bf1f-54c099792b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_8ebc8b36-1603-497e-9ab0-c3d3a203614f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1d3e92a-d18a-4c62-8236-9504c4ac1d8e" xlink:to="loc_dei_EntityEmergingGrowthCompany_8ebc8b36-1603-497e-9ab0-c3d3a203614f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45744944291760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jul. 03, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">76-0474169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lexicon Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2445 Technology Forest Blvd., 11th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">The Woodlands<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">863-3000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LXRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 13,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001062822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M6E8RUK2+;\_H;"_; L4]_3U/Y&X7KIE:\9/]JT;H:3R['?^&,96M@>+V_0)
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MY?.J>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^
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M$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ =C8P60=!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" !V-C!94B$G&.\    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " !V-C!9F5R<(Q &  "<)P  $P
M    @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( '8V,%GU
M:6@U5P0  )40   8              " @0X(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " !V-C!9GZ ;\+$"  #B#   #0
M    @ &;#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( '8V,%F7BKL<P
M !,"   +              "  7</  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M '8V,%FJQ"(6,P$  "("   /              "  6 0  !X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " !V-C!9)!Z;HJT   #X 0  &@
M@ ' $0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !V
M-C!999!YDAD!  #/ P  $P              @ &E$@  6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     "0 ) #X"  #O$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="lxrx-20240913.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lexpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="lxrx-20240913.htm">lxrx-20240913.htm</File>
    <File>lxrx-20240913.xsd</File>
    <File>lxrx-20240913_lab.xml</File>
    <File>lxrx-20240913_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "lxrx-20240913.htm": {
   "nsprefix": "lxrx",
   "nsuri": "http://lexpharma.com/20240913",
   "dts": {
    "inline": {
     "local": [
      "lxrx-20240913.htm"
     ]
    },
    "schema": {
     "local": [
      "lxrx-20240913.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "lxrx-20240913_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lxrx-20240913_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://lexpharma.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxrx-20240913.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxrx-20240913.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001062822-24-000051-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001062822-24-000051-xbrl.zip
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M  YP:BG%%:/#@STRS# <L]8VU>9M#0QIDSR4"_*=K\"!%/2/;4*=?$/VY[L
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M16YR'D'_'K^.]<TG*D_=+]T]I5_8^S]02P,$%     @ =C8P68\K367E&@
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M6]3 V[0L%F_YRKQZ>B]6/3PY.=GI'YP>[)P<[O6GNP?+D@3XOV-7ZYN1WAD
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ME_:PDU[3ZM\"U_#!1O<VOKZNO?/L=;B'U^''@4WF\+]QD:5O_A]02P,$%
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MB-+*VB)#];MCP:<O,=S[LN-J:>'6LF#?=09PQZ+,KMTV8%3>.T8/G23L(]C
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MMW1+WD+^0*2$TQ4_G;<+ZRAM*^PKM]VLZ'"U-M][Z^<%FYV>#WX#4$L#!!0
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M4W?.8O)^R65+;5&5 GGQW&TN7=T^D;:R=FNK*RU?7^7?9S;2K"K J@M87=2
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M'+^Y/]&]='^$/W[S?U!+ 0(4 Q0    ( '8V,%E"6'X\<@X  &A/   >
M          "  0    !E>&@Q,#%W861E<V5P87)A=&EO;F%G<F5E;2YH=&U0
M2P$"% ,4    " !V-C!9CRM-9>4:  "YH@  '@              @ &N#@
M97AH,3 R=V%D96-O;G-U;'1I;F=A9W)E96TN:'1M4$L! A0#%     @ =C8P
M63X77)GV$0  #6P  !$              ( !SRD  &QX<G@M,C R-# Y,3,N
M:'1M4$L! A0#%     @ =C8P6?9;86QK @  9P<  !$              ( !
M]#L  &QX<G@M,C R-# Y,3,N>'-D4$L! A0#%     @ =C8P68YXN]T+"@
M?50  !4              ( !CCX  &QX<G@M,C R-# Y,3-?;&%B+GAM;%!+
M 0(4 Q0    ( '8V,%EJ+!PIKP8  -@P   5              "  <Q(  !L
J>')X+3(P,C0P.3$S7W!R92YX;6Q02P4&      8 !@"< 0  KD\

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>lxrx-20240913_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lxrx-20240913.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2024-07-03</startDate>
            <endDate>2024-07-03</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001062822</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-09-13</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Lexicon Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">000-30111</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">76-0474169</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">2445 Technology Forest Blvd., 11th Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">The Woodlands</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">77381</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">281</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">863-3000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-13">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-14">LXRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-15">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications contextRef="c-1" id="f-16">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-17">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-18">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-19">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
